Four bispecific antibodies are now approved for relapsed or refractory multiple myeloma. They produce response rates of roughly 60 to 70 percent in heavily pretreated patients, and they are available off the shelf, without the manufacturing wait CAR T-cell therapy requires.
The constraint is not the drug. It is the first two weeks of taking it.
